辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PFE 辉瑞

未开盘 06-10 16:00:00 EDT

25.60

-0.10

-0.39%

盘后25.60

+0.000.00%

19:59 EDT

最高25.85	最低25.58	成交量3,038万
今开25.80	昨收25.70	日振幅1.05%
总市值1,456亿	流通市值1,453亿	总股本56.86亿
成交额7.79亿	换手率0.54%	流通股本56.76亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PFE","market":"US","secType":"STK","nameCN":"辉瑞","latestPrice":25.6,"timestamp":1781121600000,"preClose":25.7,"halted":0,"volume":30376160,"hourTrading":{"tag":"盘后","latestPrice":25.6,"preClose":25.6,"latestTime":"19:59 EDT","volume":3097947,"amount":79307529.505,"timestamp":1781135975078,"change":0,"changeRate":0,"amplitude":0.001563},"delay":0,"changeRate":-0.0038910505836575048,"floatShares":5675908374,"shares":5685707552,"eps":1.312648,"marketStatus":"未开盘","change":-0.1,"latestTime":"06-10 16:00:00 EDT","open":25.795,"high":25.8501,"low":25.58,"amount":779384344.50624,"amplitude":0.01051,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.312648,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1781164800000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":-819144000000,"exchange":"NYSE","adjPreClose":25.7,"dividendRate":0.067152,"preHourTrading":{"tag":"盘前","latestPrice":25.7061,"preClose":25.7,"latestTime":"09:28 EDT","volume":73997,"amount":1904885.8277679998,"timestamp":1781098134917,"change":0.0061,"changeRate":0.000237,"amplitude":0.006704},"postHourTrading":{"tag":"盘后","latestPrice":25.6,"preClose":25.6,"latestTime":"19:59 EDT","volume":3097947,"amount":79307529.505,"timestamp":1781135975078,"change":0,"changeRate":0,"amplitude":0.001563},"volumeRatio":0.884315,"impliedVol":0.2433,"impliedVolPercentile":0.2231},"requestUrl":"/m/hq/s/PFE","defaultTab":"news","newsList":[{"id":"1189869663","title":"辉瑞CEO致信德国总理：当前针对医药行业的政策正改变定价与市场环境","url":"https://stock-news.laohu8.com/highlight/detail?id=1189869663","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189869663?lang=zh_cn&edition=full","pubTime":"2026-06-10 19:17","pubTimestamp":1781090278,"startTime":"0","endTime":"0","summary":"辉瑞首席执行官在致德国总理的信函中指出，德国现行针对制药行业的政策正在显著改变药品定价机制与整体市场环境。\n这位行业领袖强调，相关政策调整已对市场运作条件产生实质性影响。他进一步阐述，这些变化不仅关乎短期定价，更可能重塑长期的产业竞争格局与创新生态。\n信函内容反映出跨国制药企业对德国这一关键市场政策动向的高度关注。随着监管环境持续演变，企业正密切关注其将对全球药品定价策略与市场准入带来的潜在连锁效应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0985481810.HKD","SG9999001176.USD","LU1894683348.USD","LU0170899867.USD","IE00BLSP4452.SGD","BK4550","LU1894683264.USD","IE00B3T34201.USD","IE0002270589.USD","SG9999011175.SGD","BK4588","LU0868494617.USD","PFE","SGXZ57979304.SGD","LU0321505439.SGD","BK4592","SG9999001176.SGD","LU1023059063.AUD","IE00B19Z3581.USD","BK4581","LU0225771236.USD","SG9999002224.SGD","BK4599","SG9999002232.USD","SG9999013999.USD","IE000M9KFDE8.USD","LU1883839398.USD","LU0225284248.USD","BK4533","LU0456855351.SGD","LU1057294990.SGD","LU0122379950.USD","BK4568","IE00BBT3K403.USD","IE00BLSP4239.USD","SG9999003800.SGD","BK4007","IE00B19Z3B42.SGD","LU0321505868.SGD","LU0058720904.USD","LU1066053197.SGD","LU2596442595.SGD","BK4534","LU0234572021.USD","LU0306806265.USD","LU0306807586.USD","BK4585","LU0289739699.SGD","LU1066051498.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182563259","title":"辉瑞CEO致信透露：公司正重新评估在德国部分既定投资的“时机与规模”","url":"https://stock-news.laohu8.com/highlight/detail?id=1182563259","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182563259?lang=zh_cn&edition=full","pubTime":"2026-06-10 19:17","pubTimestamp":1781090273,"startTime":"0","endTime":"0","summary":"辉瑞公司首席执行官在一封信函中表示，这家制药巨头正在对其在德国的部分既定投资计划的“时机与规模”进行重新评估。\n此举表明该公司正根据当前环境，审慎考量其在德国市场的资本配置策略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225284248.USD","LU0985481810.HKD","SG9999002232.USD","LU0456855351.SGD","LU1066051498.USD","LU0306806265.USD","LU0868494617.USD","LU1894683264.USD","SGXZ57979304.SGD","LU0306807586.USD","IE00B19Z3B42.SGD","BK4534","BK4599","LU0170899867.USD","LU0289739699.SGD","BK4585","SG9999001176.USD","SG9999013999.USD","BK4568","BK4550","LU0122379950.USD","IE00BLSP4452.SGD","BK4581","LU1894683348.USD","LU0234572021.USD","PFE","BK4533","BK4592","LU1883839398.USD","LU0321505439.SGD","LU0058720904.USD","LU1066053197.SGD","LU0225771236.USD","LU2596442595.SGD","LU1023059063.AUD","IE00BBT3K403.USD","IE00BLSP4239.USD","SG9999011175.SGD","LU0321505868.SGD","IE00B19Z3581.USD","IE00B3T34201.USD","SG9999001176.SGD","IE000M9KFDE8.USD","SG9999003800.SGD","BK4588","BK4007","LU1057294990.SGD","IE0002270589.USD","SG9999002224.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147583438","title":"辉瑞CEO致信：德国环境令长期投资“日益艰难”","url":"https://stock-news.laohu8.com/highlight/detail?id=1147583438","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147583438?lang=zh_cn&edition=full","pubTime":"2026-06-10 19:17","pubTimestamp":1781090273,"startTime":"0","endTime":"0","summary":"辉瑞首席执行官在一封信函中指出，德国当前的环境正使得长期投资变得“日益困难”。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1894683264.USD","LU2596442595.SGD","SG9999001176.USD","LU1023059063.AUD","IE00BLSP4239.USD","LU0306806265.USD","LU0321505868.SGD","LU0985481810.HKD","LU0868494617.USD","SG9999003800.SGD","LU0058720904.USD","PFE","LU0456855351.SGD","SG9999011175.SGD","BK4592","BK4581","BK4599","IE00BLSP4452.SGD","IE000M9KFDE8.USD","LU1066053197.SGD","LU0170899867.USD","SG9999002232.USD","BK4533","LU1057294990.SGD","LU0306807586.USD","IE00B19Z3B42.SGD","BK4534","LU1883839398.USD","IE0002270589.USD","BK4588","SG9999001176.SGD","BK4568","IE00B3T34201.USD","LU0122379950.USD","LU1066051498.USD","BK4550","LU1894683348.USD","SG9999013999.USD","SG9999002224.SGD","LU0289739699.SGD","LU0225771236.USD","BK4007","LU0225284248.USD","LU0234572021.USD","SGXZ57979304.SGD","LU0321505439.SGD","IE00B19Z3581.USD","BK4585","IE00BBT3K403.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642419178","title":"GLP-1赛道竞争加剧  辉瑞“头对头”挑战诺和诺德","url":"https://stock-news.laohu8.com/highlight/detail?id=2642419178","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642419178?lang=zh_cn&edition=full","pubTime":"2026-06-10 09:35","pubTimestamp":1781055326,"startTime":"0","endTime":"0","summary":"新华财经北京6月10日电近日，辉瑞公布其GLP-1受体激动剂埃诺格鲁肽（先维盈?）与诺和诺德司美格鲁肽（诺和盈?）的头对头研究——SLIMMER-UP-SWITCH的20周中期分析结果，显示埃诺格鲁肽在减重数值上略优于司美格鲁肽。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606103766030185.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4550","IE0002270589.USD","LU1894683264.USD","SG9999001176.USD","LU1066053197.SGD","PFE","BK4585","BK4568","LU0234572021.USD","LU1093756168.USD","LU0225284248.USD","SG9999003800.SGD","LU0058720904.USD","LU0321505868.SGD","LU1066051498.USD","IE00BZ1G4Q59.USD","BK4581","BK4007","IE00BLSP4452.SGD","LU0456855351.SGD","LU2596442595.SGD","NVOH","LU1894683348.USD","SG9999013999.USD","LU0122379950.USD","LU0306807586.USD","IE000M9KFDE8.USD","LU0289739699.SGD","LU1093756325.SGD","SG9999002224.SGD","IE00B19Z3581.USD","NVOX","IE00B19Z3B42.SGD","BK4533","LU0306806265.USD","BK4592","BK4534","BK4532","LU0154236417.USD","SG9999001176.SGD","IE00BKVL7J92.USD","IE00BLSP4239.USD","IE00B3T34201.USD","IE00BBT3K403.USD","LU0170899867.USD","LU0868494617.USD","LU1023059063.AUD","LU0225771236.USD","LU1883839398.USD","BK4599","SGXZ57979304.SGD","LU0985481810.HKD","LU0321505439.SGD","BK4588","NVO","SG9999002232.USD","SG9999011175.SGD","LU1057294990.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642137467","title":"多家药企公布“头对头”司美研究数据，诺和诺德坐不住了","url":"https://stock-news.laohu8.com/highlight/detail?id=2642137467","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642137467?lang=zh_cn&edition=full","pubTime":"2026-06-09 19:44","pubTimestamp":1781005440,"startTime":"0","endTime":"0","summary":"减肥药赛道再起波澜！因为一项减肥药的头对头研究数据，诺和诺德向辉瑞“开怼”。6月9日，减肥药巨头诺和诺德中国针对近期在2026年美国糖尿病协会（ADA）科学年会上公布的SLIMMER-UP-SWITCH研究的20周中期分析数据发布了一份说明称：“对于任何单一研究，均需在更完整的数据披露和多维度证据支持下进行综合、科学评估，避免片面解读带来的潜在误导。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606093765289066.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606093765289066.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4007","BK4599","SG9999003800.SGD","LU1894683264.USD","IE00B19Z3581.USD","LU0234572021.USD","LU2596442595.SGD","BK4532","SG9999013999.USD","IE00BLSP4239.USD","IE00BLSP4452.SGD","LU1066051498.USD","BK4592","LU0058720904.USD","LU0321505868.SGD","SG9999001176.USD","LU1093756168.USD","LU0225284248.USD","SG9999001176.SGD","LU1093756325.SGD","LU0456855351.SGD","NVOH","IE00B19Z3B42.SGD","LU0225771236.USD","BK4550","LU0306807586.USD","SGXZ57979304.SGD","LU0122379950.USD","BK4534","LU0985481810.HKD","SG9999002224.SGD","PFE","LU1023059063.AUD","LU0170899867.USD","LU1066053197.SGD","IE00B3T34201.USD","IE00BBT3K403.USD","LU0321505439.SGD","IE00BKVL7J92.USD","BK4533","LU1057294990.SGD","NVOX","BK4568","LU0289739699.SGD","LU1883839398.USD","SG9999011175.SGD","IE000M9KFDE8.USD","LU0306806265.USD","LU1894683348.USD","SG9999002232.USD","LU0154236417.USD","BK4585","BK4581","IE00BZ1G4Q59.USD","IE0002270589.USD","BK4588","NVO","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642462376","title":"辉瑞入局减重赛道，埃诺格鲁肽能否挑战司美格鲁肽？","url":"https://stock-news.laohu8.com/highlight/detail?id=2642462376","media":"澎湃新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642462376?lang=zh_cn&edition=full","pubTime":"2026-06-09 19:06","pubTimestamp":1781003160,"startTime":"0","endTime":"0","summary":"减重赛道迎来新的挑战者。在2026年美国糖尿病协会（ADA）年会上，多家国内外药企发布了GLP-1药物的研究数据，其中就包括辉瑞，其全球首个cAMP偏向型GLP-1受体激动剂——埃诺格鲁肽（Ecnoglutide）的最新临床数据作为最新突破（LateBreaking）正式公布。在全球公共卫生的宏大图景中，超重与肥胖正从生活方式问题演变为不可忽视的医疗挑战。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606093765268373.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606093765268373.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SG9999003800.SGD","LU0058720904.USD","SG9999001176.USD","IE000M9KFDE8.USD","LU0306806265.USD","LU0985481810.HKD","LU1066051498.USD","LU1066053197.SGD","PFE","SG9999011175.SGD","LU1894683264.USD","LU0225284248.USD","LU0122379950.USD","IE00BBT3K403.USD","LU0234572021.USD","IE00BLSP4452.SGD","IE0002270589.USD","LU0456855351.SGD","LU1023059063.AUD","SG9999013999.USD","BK4599","LU1894683348.USD","BK4581","IE00B19Z3B42.SGD","BK4550","BK4007","IE00BLSP4239.USD","LU0170899867.USD","SG9999001176.SGD","LU0321505868.SGD","SG9999002224.SGD","BK4568","BK4585","BK4588","LU1057294990.SGD","LU0306807586.USD","SGXZ57979304.SGD","BK4533","LU0225771236.USD","LU1883839398.USD","LU2596442595.SGD","LU0289739699.SGD","BK4534","BK4592","LU0321505439.SGD","LU0868494617.USD","IE00B19Z3581.USD","IE00B3T34201.USD","SG9999002232.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642928432","title":"FDA准辉瑞公司一款用于治疗儿童出血性疾病的药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2642928432","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642928432?lang=zh_cn&edition=full","pubTime":"2026-06-09 05:56","pubTimestamp":1780955760,"startTime":"0","endTime":"0","summary":"辉瑞公司周一表示，美国食品药品监督管理局已批准其药物Hympavzi用于预防或减少儿童及部分血友病患者的出血发作频率。　　此次批准使辉瑞的Hympavzi成为首个可用于6至11岁B型血友病儿童患者的非凝血因子疗法，无论患者是否存在抑制剂。　　Hympavzi此前已获批用于12岁及以上、体内未产生阻碍凝血蛋白合成的抗体的患者。　　在该后期临床试验中，Hympavzi显著降低了患有A型或B型血友病且伴有抑制剂的12岁及以上成人和青少年的平均年化出血率。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-09/doc-iniatxxi2161145.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1066051498.USD","BK4533","LU1066053197.SGD","IE00B19Z3B42.SGD","IE00BLSP4452.SGD","SG9999002232.USD","IE00BBT3K403.USD","BK4599","LU0234572021.USD","BK4581","SG9999002224.SGD","LU0225284248.USD","IE00B19Z3581.USD","SG9999003800.SGD","IE000M9KFDE8.USD","LU0321505868.SGD","LU0122379950.USD","LU1023059063.AUD","SGXZ57979304.SGD","SG9999001176.USD","IE00BLSP4239.USD","LU1883839398.USD","BK4568","BK4588","SG9999001176.SGD","IE00B3T34201.USD","SG9999013999.USD","BK4007","LU0306806265.USD","LU0985481810.HKD","SG9999011175.SGD","LU1894683348.USD","IE0002270589.USD","LU0306807586.USD","BK4585","LU1894683264.USD","BK4550","BK4592","LU1057294990.SGD","LU0868494617.USD","LU0289739699.SGD","LU0456855351.SGD","LU0058720904.USD","PFE","BK4534","LU0225771236.USD","LU0321505439.SGD","LU2596442595.SGD","LU0170899867.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641100049","title":"比司美格鲁肽多减35%体重！辉瑞减肥药能否突破GLP-1药物疗效瓶颈","url":"https://stock-news.laohu8.com/highlight/detail?id=2641100049","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641100049?lang=zh_cn&edition=full","pubTime":"2026-06-08 17:17","pubTimestamp":1780910222,"startTime":"0","endTime":"0","summary":"国内GLP-1减肥药市场的竞争，已从“有无”之争进入到拼疗效阶段。6月8日，辉瑞宣布其GLP-1受体激动剂埃诺格鲁肽与司美格鲁肽的头对头研究（SLIMMER-UP-SWITCH）关键数据，在2026年美国糖尿病协会（ADA）科学年会上作为“最新突破（LateBreaking）”正式公布。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606083763671017.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606083763671017.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1023059063.AUD","LU0456855351.SGD","LU1066053197.SGD","LU1093756168.USD","LU2596442595.SGD","SG9999011175.SGD","IE00BLSP4239.USD","IE00BBT3K403.USD","IE00BLSP4452.SGD","IE00B19Z3B42.SGD","LU0321505439.SGD","LU0225771236.USD","LU0306807586.USD","BK4581","LU0170899867.USD","LU1883839398.USD","NVOH","SG9999002224.SGD","IE000M9KFDE8.USD","LU0321505868.SGD","BK4550","NVO","IE00B19Z3581.USD","LU0289739699.SGD","SG9999002232.USD","IE00B3T34201.USD","LU0868494617.USD","SG9999013999.USD","BK4532","LU0225284248.USD","NVOX","BK4588","SG9999003800.SGD","BK4592","IE00BKVL7J92.USD","BK4534","BK4533","LU1894683348.USD","BK4568","SGXZ57979304.SGD","LU1894683264.USD","IE00BZ1G4Q59.USD","LU1093756325.SGD","LU1057294990.SGD","PFE","SG9999001176.SGD","LU0306806265.USD","LU0985481810.HKD","IE0002270589.USD","SG9999001176.USD","BK4599","LU0122379950.USD","BK4585","BK4007","LU0154236417.USD","LU0234572021.USD","LU1066051498.USD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141286660","title":"辉瑞GLP-1受体激动剂Berobenatide展现强劲2B期疗效与良好耐受性，支持每月给药方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1141286660","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141286660?lang=zh_cn&edition=full","pubTime":"2026-06-06 21:02","pubTimestamp":1780750961,"startTime":"0","endTime":"0","summary":"辉瑞公司研发的GLP-1受体激动剂Berobenatide，其最新公布的2B期临床试验数据展现出强劲的疗效与良好的耐受性特征。这些积极结果有力地支持了该药物采用每月一次的给药方案，为其后续开发路径奠定了坚实基础。数据表明，该候选药物在实现预期治疗目标的同时，其安全性特征亦令人鼓舞，为患者提供了潜在的新治疗选择。这一进展进一步丰富了辉瑞在代谢疾病领域的研发管线，并凸显了其在长效疗法开发方面的技术实力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999003800.SGD","LU0058720904.USD","SG9999001176.USD","IE000M9KFDE8.USD","LU0306806265.USD","LU0985481810.HKD","LU1066051498.USD","LU1066053197.SGD","PFE","SG9999011175.SGD","LU1894683264.USD","LU0225284248.USD","LU0122379950.USD","IE00BBT3K403.USD","LU0234572021.USD","IE00BLSP4452.SGD","IE0002270589.USD","LU0456855351.SGD","LU1023059063.AUD","SG9999013999.USD","BK4599","LU1894683348.USD","BK4581","IE00B19Z3B42.SGD","OZEM","BK4550","BK4007","IE00BLSP4239.USD","LU0170899867.USD","SG9999001176.SGD","LU0321505868.SGD","SG9999002224.SGD","BK4568","BK4585","BK4588","LU1057294990.SGD","LU0306807586.USD","SGXZ57979304.SGD","BK4533","LU0225771236.USD","LU1883839398.USD","LU2596442595.SGD","LU0289739699.SGD","BK4534","BK4592","LU0321505439.SGD","LU0868494617.USD","IE00B19Z3581.USD","IE00B3T34201.USD","SG9999002232.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640378531","title":"西南证券：信达生物(01801)携手辉瑞 加速创新肿瘤药物开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2640378531","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640378531?lang=zh_cn&edition=full","pubTime":"2026-06-04 14:15","pubTimestamp":1780553754,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，西南证券发布研报称，5月29日，信达生物与辉瑞达成全球战略合作，加速创新肿瘤药物开发。同时，信达保留在大中华区地区的权利；根据协议的财务条款，信达生物将获得首付款6.5亿美元，并有资格获得最高可达98.5亿美元的研发、监管与商业化里程碑付款，交易总额达105亿美元。在2026ASCO上，信达生物公布了IBI363一线治疗晚期NSCLC的临床I期PoC研究初步结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450033.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0225284248.USD","LU0455707207.USD","LU2328871848.SGD","LU2488822045.USD","LU0985481810.HKD","HK0000165453.HKD","SG9999002232.USD","LU0456855351.SGD","LU1066051498.USD","LU0306806265.USD","LU0502904849.HKD","LU0868494617.USD","LU1894683264.USD","LU2097828557.USD","SGXZ57979304.SGD","BK1583","LU2097828631.EUR","LU0306807586.USD","IE00B19Z3B42.SGD","BK4534","BK4599","LU0170899867.USD","LU0289739699.SGD","BK4585","SG9999001176.USD","SG9999013999.USD","BK4568","BK4550","LU0122379950.USD","IE00BLSP4452.SGD","BK4581","LU1894683348.USD","LU0234572021.USD","PFE","BK4533","BK4592","LU1883839398.USD","LU0321505439.SGD","LU0058720904.USD","LU1066053197.SGD","BK1589","LU2097828805.USD","LU0225771236.USD","01801","LU2097828714.EUR","LU1023059063.AUD","LU2097828474.EUR","IE00BBT3K403.USD","IE00BLSP4239.USD","SG9999011175.SGD","LU1969619763.USD","BK1161","LU0321505868.SGD","LU2242644610.SGD","IE00B19Z3581.USD","IE00B3T34201.USD","SG9999001176.SGD","IE000M9KFDE8.USD","SG9999003800.SGD","BK4588","BK4007","LU1057294990.SGD","IE0002270589.USD","SG9999002224.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2640330789","title":"【券商聚焦】中信建投维持信达生物(01801)“买入”评级 指其与辉瑞合作全球化里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=2640330789","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640330789?lang=zh_cn&edition=full","pubTime":"2026-06-01 13:55","pubTimestamp":1780293323,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券发布研报指，信达生物 与辉瑞达成全球战略合作，交易总额达105亿美元。信达生物将获得首付款6.5亿美元，并有资格获得最高达98.5亿美元的研发、监管与商业化里程碑付款，对于每一款获批项目还将获得最高达双位数比例的销售分成。中信建投预计信达生物2026-2028年收入分别为180.2亿元、243.3亿元、285.8亿元，净利润分别为22.1亿元、38.2亿元、50.1亿元。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1982638","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","BK1161","LU2328871848.SGD","01801","BK4533","LU0502904849.HKD","SG9999003800.SGD","LU2097828631.EUR","LU2097828474.EUR","BK4585","BK1589","BK4550","BK4007","LU0321505868.SGD","LU0456855351.SGD","IE00BBT3K403.USD","IE000M9KFDE8.USD","LU1023059063.AUD","BK4568","BK4534","IE00B19Z3581.USD","LU2097828714.EUR","IE00B19Z3B42.SGD","IE00B3T34201.USD","LU1894683264.USD","LU2242644610.SGD","BK4581","IE0002270589.USD","PFE","LU0306806265.USD","LU0985481810.HKD","SG9999002224.SGD","SG9999001176.USD","IE00BLSP4452.SGD","BK4588","LU2488822045.USD","LU0234572021.USD","LU2097828557.USD","LU1969619763.USD","BK4599","BK1583","LU0225284248.USD","LU1066051498.USD","LU1883839398.USD","LU2097828805.USD","SG9999011175.SGD","SGXZ57979304.SGD","LU0455707207.USD","LU0868494617.USD","IE00BLSP4239.USD","LU0306807586.USD","LU0058720904.USD","LU0170899867.USD","HK0000165453.HKD","LU1057294990.SGD","LU0225771236.USD","LU1894683348.USD","SG9999001176.SGD","SG9999013999.USD","SG9999002232.USD","LU0321505439.SGD","LU1066053197.SGD","BK4592","LU0122379950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639609623","title":"CROWN研究发布7年随访数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2639609623","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639609623?lang=zh_cn&edition=full","pubTime":"2026-05-30 20:38","pubTimestamp":1780144696,"startTime":"0","endTime":"0","summary":"2026年美国临床肿瘤学会年会（ASCO2026）上，辉瑞公司以口头报告的形式公布了III期CROWN研究的7年随访结果。该研究旨在评估第三代ALK抑制剂洛拉替尼对比第一代ALK抑制剂在既往未经治疗的间变性淋巴瘤激酶（ALK）阳性晚期或转移性非小细胞肺癌（NSCLC）患者中的疗效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605303755087691.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0058720904.USD","LU0234572021.USD","BK4534","LU1066053197.SGD","BK4533","SG9999013999.USD","LU0225284248.USD","LU0306807586.USD","IE00B19Z3B42.SGD","IE00BLSP4239.USD","SG9999011175.SGD","BK4568","LU0868494617.USD","SG9999003800.SGD","LU1883839398.USD","SG9999001176.SGD","SG9999002232.USD","IE000M9KFDE8.USD","LU0985481810.HKD","BK4500","LU1066051498.USD","LU1023059063.AUD","LU0321505439.SGD","BK4585","BK4007","LU0456855351.SGD","ALK","LU1894683348.USD","BK4008","LU0122379950.USD","IE00B3T34201.USD","PFE","SG9999001176.USD","BK4550","IE00B19Z3581.USD","LU0321505868.SGD","BK4588","IE00BLSP4452.SGD","LU0289739699.SGD","LU0225771236.USD","SG9999002224.SGD","LU0170899867.USD","BK4599","BK4592","IE00BBT3K403.USD","BK4581","LU0306806265.USD","SGXZ57979304.SGD","LU1894683264.USD","LU1057294990.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639450605","title":"信达牵手辉瑞，给中国Biopharma全球化打了个样","url":"https://stock-news.laohu8.com/highlight/detail?id=2639450605","media":"医曜","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639450605?lang=zh_cn&edition=full","pubTime":"2026-05-30 09:01","pubTimestamp":1780102881,"startTime":"0","endTime":"0","summary":"信达授予辉瑞全球独家许可权，辉瑞承担全球开发成本。这并不是第一次有中国Biopharma尝试进入全球商业化，但却是第一次以如此系统的方式、在如此大规模的框架下实现。中国Biopharma的长期估值天花板，取决于它能不能从“管线供给方”变成“全球品牌药企”。在这条路径上，Biopharma不需要卖断管线，不需要放弃全球品牌建设的可能性，可以用研发能力换取商业化能力的合伙权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8tXhUm8ykvO","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["BK4581","IE00B3T34201.USD","LU0306806265.USD","LU1894683264.USD","BK4588","BK1161","LU2097828714.EUR","LU2328871848.SGD","SGXZ57979304.SGD","SG9999003800.SGD","IE00B19Z3581.USD","IE00BBT3K403.USD","SG9999002224.SGD","LU0225284248.USD","LU0455707207.USD","SG9999001176.SGD","LU0289739699.SGD","PFE","IE000M9KFDE8.USD","LU0225771236.USD","LU0502904849.HKD","LU1057294990.SGD","LU2097828474.EUR","LU2242644610.SGD","BK1589","IE0002270589.USD","SG9999001176.USD","LU0321505439.SGD","BK4599","BK4550","IE00BLSP4239.USD","LU0170899867.USD","LU1066051498.USD","LU0985481810.HKD","SG9999013999.USD","LU2097828805.USD","LU0868494617.USD","BK4585","SG9999011175.SGD","01801","LU1883839398.USD","LU2097828631.EUR","BK4007","BK4534","LU2488822045.USD","LU1066053197.SGD","LU2097828557.USD","SG9999002232.USD","BK4592","LU1894683348.USD","HK0000165453.HKD","LU0321505868.SGD","BK4568","LU1969619763.USD","LU0058720904.USD","LU1023059063.AUD","LU0234572021.USD","BK1583","IE00BLSP4452.SGD","LU0306807586.USD","IE00B19Z3B42.SGD","LU0122379950.USD","LU0456855351.SGD","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183902216","title":"辉瑞更新营销授权获欧盟27国及冰岛、列支敦士登、挪威全面认可","url":"https://stock-news.laohu8.com/highlight/detail?id=1183902216","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183902216?lang=zh_cn&edition=full","pubTime":"2026-05-29 23:48","pubTimestamp":1780069731,"startTime":"0","endTime":"0","summary":"辉瑞公司宣布，其更新的营销授权已在欧盟全部27个成员国正式生效，并同时适用于冰岛、列支敦士登和挪威三国。此项授权更新意味着该公司相关产品在包括上述欧洲经济区国家在内的广阔区域内，具备了统一且完全合规的市场准入资格。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4592","IE0002270589.USD","LU0122379950.USD","LU0170899867.USD","LU1894683264.USD","IE00BBT3K403.USD","IE000M9KFDE8.USD","LU0058720904.USD","BK4534","LU0321505439.SGD","BK4568","LU1066051498.USD","LU0234572021.USD","SG9999013999.USD","LU1023059063.AUD","BK4007","IE00B19Z3581.USD","IE00B3T34201.USD","SG9999002224.SGD","SGXZ57979304.SGD","SG9999003800.SGD","LU0225284248.USD","LU0306807586.USD","PFE","BK4599","SG9999011175.SGD","LU1894683348.USD","BK4550","LU0225771236.USD","IE00B19Z3B42.SGD","IE00BLSP4239.USD","BK4588","IE00BLSP4452.SGD","SG9999001176.USD","LU0868494617.USD","LU1066053197.SGD","LU1883839398.USD","LU1057294990.SGD","LU0321505868.SGD","BK4581","LU0985481810.HKD","SG9999001176.SGD","LU0456855351.SGD","LU0289739699.SGD","LU0306806265.USD","BK4533","SG9999002232.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166942353","title":"欧盟委员会批准更新辉瑞-BioNTech新冠疫苗儿科使用授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1166942353","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166942353?lang=zh_cn&edition=full","pubTime":"2026-05-29 23:48","pubTimestamp":1780069705,"startTime":"0","endTime":"0","summary":"欧盟委员会已批准更新由辉瑞与BioNTech联合研发的新冠疫苗在儿科人群中的使用授权。此次更新涉及疫苗在儿童群体中的具体使用信息，标志着该疫苗在满足特定地区儿童接种需求方面取得了新的监管进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4599","SG9999003800.SGD","LU1894683264.USD","IE00B19Z3581.USD","LU0234572021.USD","SG9999013999.USD","IE00BLSP4239.USD","IE00BLSP4452.SGD","LU1066051498.USD","BK4592","LU0058720904.USD","LU0321505868.SGD","SG9999001176.USD","LU0225284248.USD","SG9999001176.SGD","LU0456855351.SGD","IE00B19Z3B42.SGD","LU0225771236.USD","BK4550","LU0306807586.USD","SGXZ57979304.SGD","LU0122379950.USD","BK4534","LU0985481810.HKD","SG9999002224.SGD","PFE","LU1023059063.AUD","LU0170899867.USD","LU1066053197.SGD","IE00B3T34201.USD","IE00BBT3K403.USD","LU0321505439.SGD","BK4533","LU1057294990.SGD","BK4568","LU0289739699.SGD","LU1883839398.USD","SG9999011175.SGD","IE000M9KFDE8.USD","LU0306806265.USD","LU1894683348.USD","SG9999002232.USD","BK4585","BK4581","IE0002270589.USD","BK4588","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156020992","title":"辉瑞与BioNTech新冠疫苗获授权，将为6个月至11岁儿童统一使用10微克剂量","url":"https://stock-news.laohu8.com/highlight/detail?id=1156020992","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156020992?lang=zh_cn&edition=full","pubTime":"2026-05-29 23:47","pubTimestamp":1780069665,"startTime":"0","endTime":"0","summary":"辉瑞公司与其合作伙伴BioNTech SE共同研发的新冠疫苗已获得授权，将面向6个月至11岁的所有儿童群体，统一采用10微克的剂量进行接种。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1894683264.USD","LU1057294990.SGD","LU0289739699.SGD","IE00BLSP4239.USD","BK4139","LU0122379950.USD","SG9999011175.SGD","BK4551","SGXZ57979304.SGD","LU0306806265.USD","LU1066053197.SGD","LU0058720904.USD","IE00BBT3K403.USD","LU0868494617.USD","BK4534","IE0002270589.USD","SG9999001176.SGD","LU0321505439.SGD","IE00B19Z3581.USD","LU0985481810.HKD","LU1894683348.USD","SG9999002224.SGD","BK4548","BK4588","LU0234572021.USD","LU1883839398.USD","SG9999013999.USD","IE00B19Z3B42.SGD","IE000M9KFDE8.USD","LU0170899867.USD","LU0225284248.USD","SG9999002232.USD","BK4533","BK4585","BK4535","BK4599","BNTX","PFE","SG9999001176.USD","BK4007","IE00BLSP4452.SGD","IE00B3T34201.USD","BK4592","BK4550","LU0225771236.USD","LU1023059063.AUD","LU0306807586.USD","LU0321505868.SGD","SG9999003800.SGD","BK4568","LU1066051498.USD","BK4581","LU0456855351.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639643171","title":"信达再获百亿美元大单，Co-Co模式从“练兵”走向常态化","url":"https://stock-news.laohu8.com/highlight/detail?id=2639643171","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639643171?lang=zh_cn&edition=full","pubTime":"2026-05-29 10:32","pubTimestamp":1780021920,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛一年之内，两次以Co-Co（共同开发与共同商业化）模式站上全球BD交易舞台的中心，信达生物正在为中国创新药出海写下新注脚。5月29日，信达生物在港交所公告，与辉瑞就12个具有突破性潜力的肿瘤早期及源头创新研发项目签署全球战略许可及合作协议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605293754033177.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605293754033177.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BMS","SG9999002232.USD","LU1894683264.USD","LU0306806265.USD","LU1023059063.AUD","BK4007","SG9999001176.SGD","LU0456855351.SGD","BK4592","SG9999001176.USD","01801","BK4599","IE00BLSP4452.SGD","LU2242644610.SGD","SGXZ57979304.SGD","SG9999011175.SGD","BK1583","IE00B19Z3B42.SGD","BK4588","LU0170899867.USD","LU1066053197.SGD","LU0321505439.SGD","IE00BBT3K403.USD","LU0321505868.SGD","LU0306807586.USD","LU0502904849.HKD","LU2097828805.USD","BK4533","LU0234572021.USD","LU2097828474.EUR","BK4585","BK4550","LU1969619763.USD","LU0225771236.USD","BK1589","IE00B19Z3581.USD","LU0289739699.SGD","LU0985481810.HKD","LU2097828714.EUR","LU0058720904.USD","LU1066051498.USD","LU2328871848.SGD","IE000M9KFDE8.USD","LU0225284248.USD","LU1057294990.SGD","LU1883839398.USD","LU1894683348.USD","BK4568","LU0122379950.USD","LU2097828557.USD","LU2097828631.EUR","IE00BLSP4239.USD","PFE","LU0868494617.USD","BK4534","BK4581","IE0002270589.USD","IE00B3T34201.USD","LU0455707207.USD","LU2488822045.USD","HK0000165453.HKD","BK1161","SG9999002224.SGD","SG9999003800.SGD","SG9999013999.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639610747","title":"港股异动 | 信达生物(01801)高开近7% 与辉瑞达成全球战略合作 交易总额将达105亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2639610747","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639610747?lang=zh_cn&edition=full","pubTime":"2026-05-29 09:24","pubTimestamp":1780017855,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，信达生物今日大幅高开，涨近7%。消息面上，信达生物今早发布公告称，公司连同其附属公司与辉瑞公司签署全球战略许可及合作协议。根据协议，信达生物将获得首付款6.5亿美元，并有资格获得最高可达98.5亿美元的研发、监管与商业化里程碑付款，交易总额达105亿美元。此外，对于每一款获批准上市的项目，信达生物将获得最高达双位数比例的销售分成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"85aa620b44b41adbca797a69a2bb2dcb","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447522.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0225284248.USD","LU1066053197.SGD","LU0306806265.USD","LU0289739699.SGD","IE00BBT3K403.USD","LU1969619763.USD","BK1583","IE00B19Z3581.USD","LU0455707207.USD","LU2097828474.EUR","LU2097828631.EUR","SG9999001176.SGD","SG9999002224.SGD","SG9999011175.SGD","BK4581","IE00BLSP4452.SGD","LU2242644610.SGD","SG9999003800.SGD","SG9999001176.USD","BK1161","IE00BLSP4239.USD","LU2097828714.EUR","IE000M9KFDE8.USD","LU2488822045.USD","LU1883839398.USD","PFE","BK4592","LU0321505439.SGD","LU0321505868.SGD","LU1023059063.AUD","SG9999002232.USD","IE00B3T34201.USD","LU1894683348.USD","LU0985481810.HKD","LU1894683264.USD","LU0502904849.HKD","BK4007","BK4534","LU0868494617.USD","LU2097828557.USD","LU2328871848.SGD","LU0456855351.SGD","LU1057294990.SGD","LU0170899867.USD","BK4588","LU2097828805.USD","IE0002270589.USD","LU0306807586.USD","LU0122379950.USD","LU1066051498.USD","BK1589","SG9999013999.USD","01801","BK4599","BK4585","BK4568","BK4550","LU0225771236.USD","HK0000165453.HKD","BK4533","LU0234572021.USD","IE00B19Z3B42.SGD","SGXZ57979304.SGD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639861406","title":"智通港股早知道 | 国务院印发《城市更新“十五五”规划》 商务部：中美原则同意讨论同等规模产品对等降税框架安排","url":"https://stock-news.laohu8.com/highlight/detail?id=2639861406","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639861406?lang=zh_cn&edition=full","pubTime":"2026-05-29 07:20","pubTimestamp":1780010426,"startTime":"0","endTime":"0","summary":"商务部：中美原则同意讨论同等规模产品对等降税框架安排 规模各为300亿美元或更多商务部新闻发言人何亚东28日在例行新闻发布会上回应关于中美关税谈判进展的提问时表示，关税一直是中美经贸关系中的关键问题之一。同时，双方原则同意在贸易理事会项下讨论同等规模产品对等降税框架安排，规模各为300亿美元或更多。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447483.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1116320737.USD","LU2491049909.HKD","LU2294711713.HKD","LU0634319403.HKD","LU1035773651.USD","LU0823421333.USD","BK4134","LU1718418525.SGD","LU0158827948.USD","LU1935042991.SGD","IE00B19Z3B42.SGD","BK4550","LU0444971666.USD","LU2125154935.USD","SG9999001077.SGD","LU0029864427.USD","SG9999015986.USD","LU1261432733.SGD","LU1571399168.USD","BK1163","LU0079474960.USD","BK4612","LU0289961442.SGD","LU0211328371.USD","LU2476274720.SGD","LU2476274308.USD","IE0002270589.USD","LU1989764748.USD","LU0557290698.USD","688981","LU1732799900.SGD","LU0348735423.USD","LU0784385170.HKD","LU1880398471.USD","LU2764262908.HKD","LU2750360641.GBP","LU2463028550.USD","BK4598","LU0823417737.USD","LU2322448957.HKD","LU0449515922.USD","LU2237443895.HKD","LU2092937221.SGD","IE00BD6J9T35.USD","LU0889566641.SGD","LU1334329650.SGD","LU2433249047.HKD","LU2357305700.SGD","LU2505996681.GBP","SG9999018865.SGD","LU0516423091.SGD","LU0345774631.USD","LU2420271590.USD","LU2097828805.USD","LU2168563687.JPY","IE0009G5SDU7.USD","LU0516422952.EUR","BK4528","LU2250418816.HKD","LU1934455277.USD","LU1032955483.USD","LU2125154778.USD","LU0143863198.USD","LU1564329032.USD","LU2023250330.USD","LU2089284900.SGD","BK4576","IE00B19Z8W00.USD","BK1522","IE00B19Z9505.USD","LU0289739343.SGD","LU2148611432.USD","BK4568","LU2355687059.USD","LU0965509101.SGD","BK4605","LU0061474960.USD","LU1794554557.SGD","LU2298321311.HKD","ARMG","LU0323591593.USD","LU2361044865.SGD","BK4532","LU1153585028.USD","BK1116","LU0327786744.USD","LU0456855351.SGD","LU0605514214.HKD","LU0072462426.USD","AMDS","LU0006306889.USD","IE00BK4W5L77.USD","LU0861579265.USD","LU0553294199.USD","LU0348805143.USD","LU2362541273.HKD","LU0308772762.SGD","BK1540","BK1587","LU0175139822.USD","SG9999014559.SGD","LU0170899867.USD","LU2279689827.SGD","LU1880398554.USD","LU1935042488.USD","LU0254981946.USD","IE000ITXATA3.USD","IE00BYXW3230.USD","IE0003U64NQ7.SGD","LU0128522744.USD","LU2471134952.CNY","LU0588545490.SGD","IE00B5949003.HKD","AMDW","LU0650527681.SGD","LU0039217434.USD","LU2637965513.SGD","IE00B1BXHZ80.USD","00179","BK4566","BK1521","MSFX","SG9999002232.USD","SGXZ81514606.USD","IE00BSNM7G36.USD","LU2168564222.USD","MSFY","BK4592","LU1244550494.USD","LU2404859667.USD","BK1526","AMUU","LU0244354667.USD","LU0949170426.SGD","LU1564329115.USD","LU2357125470.USD","AMDY","BK4573","LU1145028129.USD","LU0690374615.EUR","LU0856984785.SGD","03600","IE00B775SV38.USD","LU2168564495.EUR","LU2023250843.SGD","LU2077746001.SGD","IE00BJTD4V19.USD","03388","LU1720050803.USD","LU2125909247.SGD","IE00BFXG0V08.USD","LU1188199696.SGD","LU2211815571.USD","02172","LU1506573853.SGD","LU1883839398.USD","LU0594300419.USD","LU2413666426.HKD","LU0828238088.HKD","LU1228905037.USD","LU0964807845.USD","LU0316494557.USD","IE0001KFT4U8.USD","LU1228905540.USD","JEHLY","LU0912757837.SGD","LU0354030438.USD","LU2237957902.USD","LU0149725797.USD","LU1043141123.HKD","LU0531970944.HKD","LU1894683348.USD","IE00BJJMRY28.SGD","ATHM","LU0820562030.AUD","LU0708995583.HKD","LU2860962120.EUR","LU0823414551.USD","LU2456880835.USD","LU0061475181.USD","LU0097036916.USD","LU1548497426.USD","IE00BQXX3D17.EUR","GB00B4LPDJ14.GBP","LU0269904917.USD","LU0229945570.USD","LU1564329461.SGD","LU0107464264.USD","LU1236620750.USD","LU0345768153.USD","LU2092937148.SGD","LU1961090484.USD","SG9999002828.SGD","LU0094547139.USD","LU0819121731.USD","LU2322448791.USD","LU0823417653.USD","LU2602419157.SGD","LU0054450605.USD","LU0868494617.USD","SG9999001424.SGD","LU1301847155.USD","LU2236285917.USD","LU0095938881.EUR","LU2506951792.HKD","LU2242649171.HKD","LU0214875030.USD","LU1059921491.USD","IE00B4YYXB79.USD","LU0061474705.USD","LU1670628061.USD","IE00BBT3K403.USD","BK4579","LU0080751232.USD","LU0348723411.USD","LU1496350171.SGD","LU0072461881.USD","LU2348774022.SGD","IE0034235295.USD","BK4141","LU2065169927.USD","LU1868837136.USD","LU2506952170.USD","LU2750360997.AUD","IE0004445239.USD","LU0310799852.SGD","LU1119994496.HKD","LU1251922891.USD","LU1066051498.USD","LU2111349929.HKD","LU1732800096.USD","LU1037948541.HKD","LU1629891620.HKD","GLWG","LU1670710588.SGD","LU2360032135.SGD","LU2092627202.USD","LU1069344957.HKD","LU1585245621.USD","LU2430703178.SGD","LU0225284248.USD","600030","LU0472753341.HKD","IE0034235188.USD","LU0234570918.USD","LU0165289439.USD","LU2471134523.USD","LU1564329628.SGD","LU2097344357.USD","LU0683600562.USD","LU2360108059.USD","IE0034235303.USD","LU0057025933.USD","LU0689626769.HKD","LU0594300179.USD","SG9999001226.SGD","LU0449509016.USD","IE0009356076.USD","LU1992135399.USD","LU1057294990.SGD","LU2041044095.USD","LU2097828474.EUR","LU0572944931.SGD","LU2125909593.SGD","002594","IE00BKPKM429.USD","IE00B7KXQ091.USD","CIIHY","BK4588","LU1861127337.USD","LU1814569148.SGD","LU2247934214.USD","IE00BHPRN162.USD","LU0265550359.USD","LU1852331112.SGD","LU0417517546.SGD","LU0494093205.USD","LU0463099449.HKD","BYDDY","LU0162691827.USD","LU2237443382.USD","IE0004445015.USD","IE00BYQQ9H92.USD","GB00BDT5M118.USD","LU2097344431.USD","LU2065170008.USD","LU2764263203.CNY","LU0788109477.HKD","LU2430703251.USD","XPEV","BK4529","LU2168564149.EUR","HK0000165453.HKD","LU2506951875.HKD","LU1116320901.HKD","LU1196500208.SGD","BK4585","LU0965509010.AUD","LU0082616367.USD","LU1633808545.USD","LU0345769128.USD","LU1582986359.USD","LU1989772923.USD","LU1023057109.AUD","BK1100","LU0545039389.USD","LU2237443978.SGD","LU0157215616.USD","SG9999001176.SGD","LU1435385759.SGD","LU0203202063.USD","LU0266013472.USD","BK1607","IE00BZ1G4Q59.USD","LU0043850808.USD","LU0211327993.USD","LU0315178854.USD","LU0985481810.HKD","LU1983260115.SGD","LU2275660780.HKD","SG9999014575.USD","LU1202635105.USD","LU0256863902.USD","IE00BQXX3C00.GBP","IE00BN29S564.USD","IE00BLSP4452.SGD","LU0661504455.SGD","LU1839511570.USD","LU2168564065.EUR","BK1593","LU0738911758.USD","LU0289960550.SGD","LU0323239441.USD","LU0593848301.USD","LU0757359954.USD","LU0048584097.USD","LU0784383803.USD","LU1003077747.HKD","LU0096362180.USD","SG9999015358.SGD","LU1989764664.SGD","HYDD.SI","06030","LU0070217475.USD","SG9999015978.USD","LU1242518931.SGD","LU1674673691.USD","LU0359202008.SGD","BK1539","HK0000914660.USD","LU1400636491.USD","LU1868836914.USD","SG9999014898.SGD","LU2764263039.SGD","LU0052750758.USD","LU1400636657.SGD","LU0198837287.USD","BK1119","LU0426412945.USD","LU0342679015.USD","LU0345768740.USD","LU2778985437.USD","LU0894485498.HKD","HK0000819398.USD","LU0077335932.USD","LU0306807586.USD","LU0476273544.USD","LU0787776722.HKD","LU0965509283.SGD","SG9999014880.SGD","IE00B5TLWC47.USD","GLW","IE00BJJMRX11.SGD","LU2746668974.SGD","LU0871640123.AUD","LU1582987597.SGD","LU2756315318.SGD","SG9999014542.SGD","LU0820561818.USD","LU0323240290.USD","LU2360106780.USD","BK4548","SG9999002224.SGD","LU1861558580.USD","LU1127390331.HKD","LU2054465674.USD","LU0320764243.SGD","LU1235294995.USD","PFE","LU0359201612.USD","LU1861214812.USD","BK4516","LU0417516738.SGD","LU2087621335.USD","LU2097828557.USD","LU2153592121.USD","LU2028103732.USD","IE00B775H168.HKD","LU0588545730.USD","LU1046421795.USD","LU2272731600.USD","LU2242644610.SGD","BK4543","LU2272731865.HKD","LU1066051225.USD","LU2210149790.SGD","LU2506952097.USD","LU2191332357.HKD","LU0359201885.HKD","IE00B4JS1V06.HKD","LU1989763005.USD","LU2471134879.HKD","LU2098885051.SGD","LU0690374961.EUR","LU1242518857.USD","LU1868836757.USD","LU2756315664.SGD","LU1244550221.USD","LU0889565833.HKD","LU0345770993.USD","00580","LU0545562505.USD","LU0823039010.USD","LU1808992512.USD","LU1803068623.USD","MSFU","LU0187121727.USD","LU2039709279.SGD","LU1221951046.USD","HK0000304797.USD","BK1509","BK4535","LU1551013342.USD","LU1880383440.USD","SGXZ31699556.SGD","LU1670711123.USD","LU1813983027.USD","LU2413666699.HKD","AMYY","LU2213496289.HKD","LU1670710661.SGD","LU2065171311.SGD","LU2720916845.USD","LU2286300806.USD","LU0792757196.USD","LU1064131342.USD","MSFO","LU2237957811.SGD","LU0588545904.SGD","LU0124676726.USD","LU0210533765.USD","LU0509642566.USD","LU0561508036.HKD","IE00BZ08YR35.GBP","LU1400636574.HKD","SG9999015341.SGD","LU1642822529.SGD","LU0516423174.USD","LU0516422366.SGD","SG9999002950.SGD","LU1244550577.SGD","LU0320765059.SGD","LU0879622024.SGD","LU0171293334.USD","LU2272731782.SGD","SG9999011175.SGD","LU1267930573.SGD","LU1791710582.SGD","SG9999014906.USD","IE00BFMHRM44.USD","LU1188198961.HKD","LU1232071149.USD","LU0158827781.USD","BK1516","BK4503","LU0029874905.USD","LU0314109678.HKD","LU0274383776.USD","IE00BMPRXN33.USD","BK4575","LU1868837722.USD","LU2461242641.AUD","LU0128525929.USD","LU0757359368.USD","LU2065171402.SGD","LU0640476718.USD","IE00BJTD4N35.SGD","IE00BJLML261.HKD","BK1594","LU2271345857.HKD","LU1720051017.SGD","LU1861219969.SGD","LU2347655156.SGD","LU0348827113.USD","LU0321505868.SGD","LU2746668461.USD","LU2244417387.USD","LU2543165471.USD","LU0154236417.USD","LU0053666078.USD","BK1161","LU1181866309.USD","LU2237438978.USD","LU2087625088.SGD","SGXZ99366536.SGD","IE00BFSS8Q28.SGD","LU0109392836.USD","LU1719994722.HKD","LU0865486749.SGD","BK4587","LU0689472784.USD","LU2097829019.USD","IE00BK4W5M84.HKD","LU2097828714.EUR","LU0310800379.SGD","LU1121112475.USD","LU1221951129.SGD","LU2106854487.HKD","BK1583","09868","IE0004091025.USD","LU0174119429.USD","LU2473716301.USD","LU2326559502.SGD","LU2896262040.SGD","LU1691799644.USD","BK1095","LU0289739699.SGD","LU2361045086.USD","LU2592432038.USD","BK1147","LU0949170772.SGD","LU0081259029.USD","LU0957791311.USD","SGXZ51526630.SGD","LU0256863811.USD","SGXZ57979304.SGD","BK1588","BK4567","LU1868836591.USD","LU1236620834.HKD","LU2452424414.USD","BK1589","LU0726765562.USD","LU2083900584.USD","LU0820561909.HKD","LU1815333072.USD","IE00BKVL7J92.USD","LU1935043023.USD","LU1035775433.USD","LU1074936037.SGD","LU2487616109.SGD","BK4148","LU1934455194.USD","LU2404859741.USD","LU0708994859.HKD","LU1235295455.SGD","IE00B19Z8X17.USD","LU0251132253.USD","LU2362540622.SGD","01801","LU0056508442.USD","LU1923622614.USD","BK4097","LU1623119135.USD","IE00BMPRXR70.SGD","BK1614","LU0225771236.USD","LU0276348264.USD","LU1066053197.SGD","LU1670711040.USD","LU2089985449.USD","LU2552382132.HKD","LU1582987324.SGD","LU1791710400.SGD","SG9999014914.USD","LU0708995153.HKD","BK4007","IE000M9KFDE8.USD","LU0122379950.USD","IE00BFSS7M15.SGD","LU1880383366.USD","BK1610","BK1575","SG9999014567.USD","SG9999013999.USD","LU2403377893.USD","LU0058720904.USD","BK4599","LU0426417589.USD","LU1804176565.USD","LU0708995401.HKD","LU1340139317.AUD","LU1316542783.SGD","LU0347712357.USD","LU1934455863.HKD","LU1770034418.SGD","BK4525","IE00BN8TJ469.HKD","LU1712237335.SGD","IE000KEQY171.SGD","LU2381873111.SGD","BK4554","LU0289941410.SGD","LU1989773731.SGD","LU2242650005.HKD","LU1430594728.SGD","HK0000914686.HKD","LU2471134796.USD","LU2328871848.SGD","LU0096364046.USD","LU0642271901.SGD","IE000W1ABFV2.USD","LU1778281490.HKD","02518","AMDL","LU2506951958.HKD","IE0004086264.USD","LU0345774391.USD","LU0390134368.USD","LU0823426480.USD","LU1366192091.USD","LU0203201768.USD","LU0540923850.HKD","LU1303367103.USD","LU1551013425.SGD","LU1032466523.USD","SG9999004303.SGD","LU0894486033.HKD","LU0943347566.SGD","IE00BZ08YS42.EUR","LU1084165304.USD","LU0353189763.USD","LU1267930730.SGD","LU0265550946.USD","LU1496350502.SGD","LU1823568750.SGD","LU0784384876.USD","SG9999002463.SGD","BK4577","IE000YTNTUN2.SGD","LU2108987350.USD","81211","LU0106261372.USD","LU1992135472.HKD","LU1303224171.USD","LU0109391861.USD","LU2931357623.SGD","LU2100268510.USD","HK0000532082.HKD","SG9999006597.SGD","LU1969619763.USD","LU0823421416.USD","ARMW","LU0312595415.SGD","LU1868838027.USD","LU2133065610.SGD","IBM","LU1670627923.USD","ARM","LU0320764599.SGD","SG9999015945.SGD","LU1645745479.HKD","IE00B1XK9C88.USD","LU2063271972.USD","LU2023251221.USD","00981","LU0724617625.USD","LU0164872284.USD","LU1429558221.USD","LU0784385840.USD","LU2491050154.USD","LU1721428933.USD","LU1069347547.HKD","LU0960925559.SGD","LU2458330243.SGD","LU0823038988.USD","MSFW","LU2552382215.SGD","LU0505663152.USD","LU0819123356.HKD","AMDG","LU1988902786.USD","LU0511384066.AUD","IE0005OL40V9.USD","LU0871576103.HKD","LU1815336760.USD","LU1917777945.USD","SG9999000418.SGD","AMD","LU1720051108.HKD","BK4609","LU3102509885.SGD","LU0882574139.USD","IE00B19Z3581.USD","LU0979878070.USD","BK4602","LU2237443465.HKD","LU1914381329.SGD","LU1323610961.USD","LU0985320562.USD","LU0348825331.USD","LU1267930490.SGD","LU0354030511.USD","SG9999015952.SGD","ARMU","SG9999018857.SGD","IE00BDRTCR15.USD","BK1144","LU0326950275.SGD","LU1043141396.HKD","SGXZ23171101.USD","LU0543330566.HKD","LU1328277881.USD","IE00BKDWB100.SGD","IE00BQXX3F31.USD","LU0238689110.USD","LU1868837565.USD","BK4504","GB00B4QBRK32.GBP","LU0302445910.USD","LU1935042215.USD","AMDD","LU0011850046.USD","LU0417516902.SGD","LU0469268626.HKD","LU0957808578.USD","IE00B3S45H60.SGD","LU0210536198.USD","LU1023059063.AUD","DAMD","LU0345769631.USD","LU0321505439.SGD","LU0795875086.SGD","LU2237443549.SGD","LU1674673428.USD","IE00BZ08YT58.USD","LU0127658192.USD","LU2488822045.USD","LU2552382058.USD","BK1615","LU1697837992.HKD","LU0950375773.USD","LU2449936058.SGD","LU2462591350.SGD","BK1582","LU0588546209.SGD","BK4534","LU0531971595.HKD","LU0795875169.SGD","IE00BDCRKT87.USD","LU0466842654.USD","LU0234572021.USD","LU0516422440.USD","LU0965508806.USD","BK4614","LU2361044949.HKD","LU2347655073.USD","LU0225283273.USD","LU0353189680.USD","LU1267930813.SGD","LU0823414478.USD","LU1935043536.SGD","LU0823434583.USD","SG9999003800.SGD","LU0210528500.USD","LU1066051811.HKD","BK4533","01211","IE00B3SWFQ91.USD","LU0444973449.USD","LU0133085943.USD","LU0672654240.SGD","LU2264538146.SGD","LU2097828631.EUR","HK0000304805.HKD","LU0211977185.USD","LU1923623000.USD","LU0502904849.HKD","LU2362541513.USD","LU2210150020.SGD","LU2462157665.USD","BK4538","LU1366333091.USD","LU0267386448.USD","BK1564","LU0227179875.USD","LU2505996509.AUD","LU2458330169.SGD","IE00BMPRXQ63.HKD","LU0455707207.USD","LU1803068979.SGD","LU0069063385.USD","LU0306806265.USD","LU2265009873.SGD","BK4512","LU0823434740.USD","LU1037948897.HKD","MSFT","LU0084288322.USD","LU1951200564.SGD","LU2237443622.USD","LU1280957306.USD","LU1974910355.USD","LU0719512351.SGD","LU1861559042.SGD","LU2095319765.USD","LU0215105999.USD","LU0528227936.USD","LU0138981039.USD","LU2417539215.USD","MSFD","LU2491050071.SGD","LU2089283258.USD","LU0314104364.USD","IE00BWXC8680.SGD","LU0143863784.USD","LU0314106906.USD","LU1951198990.SGD","SG9999001176.USD","LU2360107325.USD","LU2399975544.HKD","SG9999014674.SGD","BK4527","LU0259732245.USD","LU1868837300.USD","AMDU","LU2023250504.SGD","LU2249611893.SGD","LU1670756490.USD","IE00B3T34201.USD","BK4581","LU1894683264.USD","LU0164865239.USD","LU2430703095.HKD","IE00BLSP4239.USD","SG9999017495.SGD","SG9999006514.SGD","LU0307460666.USD","MSFL","LU2047632596.USD","LU1582986433.USD","LU0994945656.USD","LU0823426308.USD","LU0345770308.USD","LU1989772840.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639614132","title":"信达生物(01801)与辉瑞达成全球战略合作 加速创新肿瘤药物开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2639614132","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639614132?lang=zh_cn&edition=full","pubTime":"2026-05-29 06:55","pubTimestamp":1780008918,"startTime":"0","endTime":"0","summary":"协议亦载列以下许可及商业化安排：信达与辉瑞将在全球范围内共同开发4个关键项目，并共同承担开发成本。同时，信达生物保留在大中华区地区的权利;信达授予辉瑞4个项目于大中华区以外地区的独家许可权，辉瑞将承担大部分开发成本;信达授予辉瑞4个项目的全球独家许可权，辉瑞将承担全球开发成本。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"85aa620b44b41adbca797a69a2bb2dcb","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0058720904.USD","LU0234572021.USD","BK4534","LU1066053197.SGD","BK4533","SG9999013999.USD","LU0225284248.USD","LU0306807586.USD","LU2097828631.EUR","IE00B19Z3B42.SGD","LU2328871848.SGD","IE00BLSP4239.USD","SG9999011175.SGD","BK4568","LU0868494617.USD","SG9999003800.SGD","LU2097828805.USD","LU1883839398.USD","SG9999001176.SGD","LU2242644610.SGD","SG9999002232.USD","LU0455707207.USD","IE000M9KFDE8.USD","LU0985481810.HKD","LU1066051498.USD","LU1023059063.AUD","LU0321505439.SGD","LU2097828557.USD","BK4585","LU2097828714.EUR","BK4007","LU0456855351.SGD","01801","LU1894683348.USD","BK1589","LU0122379950.USD","PFE","IE00B3T34201.USD","SG9999001176.USD","BK4550","IE00B19Z3581.USD","BK1161","LU0321505868.SGD","LU2097828474.EUR","BK4588","IE00BLSP4452.SGD","HK0000165453.HKD","LU0289739699.SGD","LU0225771236.USD","LU0502904849.HKD","LU1969619763.USD","SG9999002224.SGD","IE0002270589.USD","LU2488822045.USD","LU0170899867.USD","BK4599","BK4592","IE00BBT3K403.USD","BK4581","BK1583","LU0306806265.USD","SGXZ57979304.SGD","LU1894683264.USD","LU1057294990.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pfizer.com","stockEarnings":[{"period":"1week","weight":0.0103},{"period":"1month","weight":-0.0081},{"period":"3month","weight":-0.0469},{"period":"6month","weight":-0.0097},{"period":"1year","weight":0.0535},{"period":"ytd","weight":0.0281}],"compareEarnings":[{"period":"1week","weight":-0.0382},{"period":"1month","weight":-0.0188},{"period":"3month","weight":0.0891},{"period":"6month","weight":0.0641},{"period":"1year","weight":0.2029},{"period":"ytd","weight":0.0638}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"辉瑞公司于1942年6月2日根据特拉华州法律成立。公司是一家以研究为基础的全球性生物制药公司。公司运用科学和全球资源，通过发现、开发、制造和分销保健产品（包括创新药物和疫苗），为人们带来延长和显著改善其生活的疗法。公司在发达国家和新兴市场开展工作，致力于促进健康、预防、治疗和治愈这个时代最令人恐惧的疾病。公司与医疗保健提供商、政府和当地社区合作，支持并扩大在全球范围内获得可靠、负担得起的医疗保健服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.456522,"avgChangeRate":0.002542},{"month":2,"riseRate":0.456522,"avgChangeRate":-0.005934},{"month":3,"riseRate":0.608696,"avgChangeRate":0.014732},{"month":4,"riseRate":0.574468,"avgChangeRate":0.016819},{"month":5,"riseRate":0.489362,"avgChangeRate":0.007168},{"month":6,"riseRate":0.489362,"avgChangeRate":0.002267},{"month":7,"riseRate":0.478261,"avgChangeRate":0.011357},{"month":8,"riseRate":0.456522,"avgChangeRate":0.0002},{"month":9,"riseRate":0.456522,"avgChangeRate":0.004432},{"month":10,"riseRate":0.630435,"avgChangeRate":0.013042},{"month":11,"riseRate":0.695652,"avgChangeRate":0.028255},{"month":12,"riseRate":0.5,"avgChangeRate":0.008452}],"exchange":"NYSE","name":"辉瑞","nameEN":"Pfizer"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供辉瑞(PFE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"辉瑞,PFE,辉瑞股票,辉瑞股票老虎,辉瑞股票老虎国际,辉瑞行情,辉瑞股票行情,辉瑞股价,辉瑞股市,辉瑞股票价格,辉瑞股票交易,辉瑞股票购买,辉瑞股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供辉瑞(PFE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}